How Analysts Feel About MediciNova, Inc. (MNOV) After Today’s Significant Increase?

February 15, 2018 - By Adrian Mccoy

Investors sentiment increased to 2.67 in 2017 Q3. Its up 1.21, from 1.46 in 2017Q2. It increased, as 2 investors sold MediciNova, Inc. shares while 7 reduced holdings. 4 funds opened positions while 20 raised stakes. 7.88 million shares or 0.85% more from 7.81 million shares in 2017Q2 were reported.
Tiaa Cref Investment Management Limited holds 0% or 90,295 shares in its portfolio. Nationwide Fund Advsr invested in 0% or 16,991 shares. Jane Street Gp Limited holds 18,600 shares. Bnp Paribas Arbitrage Sa holds 3,168 shares or 0% of its portfolio. Natl Bank Of Mellon Corp has invested 0% in MediciNova, Inc. (NASDAQ:MNOV). Goldman Sachs invested in 25,863 shares or 0% of the stock. State Of Wisconsin Board holds 0% or 26,000 shares. Manufacturers Life Insur Company The reported 0% of its portfolio in MediciNova, Inc. (NASDAQ:MNOV). California State Teachers Retirement Sys has 0% invested in MediciNova, Inc. (NASDAQ:MNOV). Deutsche Retail Bank Ag has 31,136 shares. Fmr Limited Liability Corp, Massachusetts-based fund reported 1.18M shares. Morgan Stanley reported 0% of its portfolio in MediciNova, Inc. (NASDAQ:MNOV). Schwab Charles Inv Management accumulated 0% or 46,400 shares. Dimensional Fund Advsr Ltd Partnership has 0% invested in MediciNova, Inc. (NASDAQ:MNOV). Blackrock Inc has 0% invested in MediciNova, Inc. (NASDAQ:MNOV).

The stock of MediciNova, Inc. (NASDAQ:MNOV) is a huge mover today! The stock increased 7.95% or $0.785 during the last trading session, reaching $10.655. About 278,031 shares traded or 39.03% up from the average. MediciNova, Inc. (NASDAQ:MNOV) has declined 6.61% since February 15, 2017 and is downtrending. It has underperformed by 23.31% the S&P500.
The move comes after 9 months positive chart setup for the $436.09 million company. It was reported on Feb, 15 by Barchart.com. We have $11.61 PT which if reached, will make NASDAQ:MNOV worth $39.25M more.

More notable recent MediciNova, Inc. (NASDAQ:MNOV) news were published by: Globenewswire.com which released: “MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in …” on February 01, 2018, also Fool.com with their article: “Here’s Why MediciNova, Inc. Stock Is Sliding Today” published on February 08, 2018, Globenewswire.com published: “MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation …” on January 30, 2018. More interesting news about MediciNova, Inc. (NASDAQ:MNOV) were released by: Globenewswire.com and their article: “MediciNova to Present at the 98th Annual Meeting of the Chemical Society of Japan” published on January 16, 2018 as well as Globenewswire.com‘s news article titled: “MediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 …” with publication date: January 31, 2018.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company has market cap of $436.09 million. The companyÂ’s product candidate includes MN-166 , an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. It currently has negative earnings. The Company’s product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.